Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Charles J. Ryan, Matthew Raymond Smith, Johann Sebastian De Bono, Arturo Molina, Christopher Logothetis, Paul L. De Souza, Karim Fizazi, Paul N. Mainwaring, Jose Maria Piulats Rodriguez, Siobhan Ng, Joan Carles, Peter Mulders, Thian San Kheoh, Thomas W. Griffin, Eric Jay Small, Howard I. Scher, Dana E. Rathkopf, on behalf of the COU-AA-302 Investigators
Institutions: University of California, San Francisco, Massachusetts General Hospital, Institute of Cancer Research, Royal Marsden Hospital, The University of Texas MD Anderson Cancer Center, St George Hospital, Institut Gustave Roussy, Institut Català d'Oncologia, St John of God Subiaco Hospital, Vall d'Hebron Hospital Universitari, Radboud University Medical Center, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2216669254